Liu Changya, Wu Xinxin, Yang Hongqiang, Xu Xiangru, Chen Caiyu, Wu Linguangjin, Zhang Wen, Shi Haimei, Fei Yuerong, Sun Yuting, Wu Hongze, Zhou Shuang, Fang Bangjiang
Department of Emergency, LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shanghai Skin Disease Hospital, Tongji University Skin Disease Hospital, Shanghai, China.
Front Pharmacol. 2023 Jul 20;14:1185122. doi: 10.3389/fphar.2023.1185122. eCollection 2023.
Reyanning mixture has been demonstrated to be effective in treating infected patients during the outbreak pandemic of SARS-CoV-2 Omicron variant of Coronavirus disease 2019 (COVID-19) in Shanghai 2022. The aim of this study is to further investigate the role of Reyanning mixture specifically in the treatment of elderly patients. This study enrolled 1,102 elderly patients who were infected with SARS-CoV-2 Omicron variant. Of these, 291 patients received Reyanning mixture in conjunction with conventional Western medicine treatment were assigned to the treatment group, while 811 patients only received conventional Western medicine treatment were assigned to the control group. Clinical parameters including hospitalization duration, viral shedding time, and Cycle Threshold (Ct) values of novel coronavirus nucleic acid tests, as well as adverse events were recorded and analyzed in both groups. There was no significant difference in baseline characteristics between two groups. In comparison to the control group, the treatment group demonstrated a substantial difference in hospitalization duration (median: 8 days vs. 10 days, HR: 0.638, 95% CI: 0.558-0.731, < 0.001). The treatment group also showed a significantly shorter viral shedding time compared to the control group (median: 7 days vs. 8 days, HR: 0.754, 95% CI: 0.659-0.863, < 0.001). Multivariate Cox proportional-hazards model analysis indicated that the use of Reyanning mixture was closely associated with a reduction in hospitalization duration (HR: 1.562, 95% CI: 1.364-1.789, < 0.001) and viral shedding time (HR: 1.335, 95% CI: 1.166-1.528, < 0.001). In addition, during the treatment process, no serious adverse event occurred in either group. The improvement of clinical parameters in the treatment group indicate a promising therapeutic benefit of Reyanning mixture for elderly patients infected with SARS-CoV-2 Omicron variant in the present study. Further investigations are required to validate this finding by examining the underlying mechanism and function of Reyanning mixture.
在2022年上海新型冠状病毒肺炎（COVID-19）奥密克戎变异株大流行期间，已证明热炎宁合剂对感染患者有效。本研究的目的是进一步研究热炎宁合剂在治疗老年患者中的具体作用。本研究纳入了1102例感染新型冠状病毒奥密克戎变异株的老年患者。其中，291例接受热炎宁合剂联合传统西药治疗的患者被分配到治疗组，而811例仅接受传统西药治疗的患者被分配到对照组。记录并分析两组患者的临床参数，包括住院时间、病毒清除时间、新型冠状病毒核酸检测的循环阈值（Ct）值以及不良事件。两组患者的基线特征无显著差异。与对照组相比，治疗组的住院时间有显著差异（中位数：8天对10天，HR：0.638，95%CI：0.558-0.731，<0.001）。治疗组的病毒清除时间也明显短于对照组（中位数：7天对8天，HR：0.754，95%CI：0.659-0.863，<0.001）。多变量Cox比例风险模型分析表明，使用热炎宁合剂与住院时间缩短（HR：1.562，95%CI：1.364-1.789，<0.001）和病毒清除时间缩短（HR：1.335，95%CI：1.166-1.528，<0.001）密切相关。此外，在治疗过程中，两组均未发生严重不良事件。治疗组临床参数的改善表明，在本研究中热炎宁合剂对感染新型冠状病毒奥密克戎变异株的老年患者具有良好的治疗效果。需要进一步研究以通过研究热炎宁合剂的潜在机制和功能来验证这一发现。
